[The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen].

Xu, Z F; Qin, T J; Zhang, H L; Fang, L W; Zhang, Y; Pan, L J; Hu, N B; Qu, S Q; Li, B; Xiao, Z J

Xu, Z F; Qin, T J; Zhang, H L; Fang, L W; Zhang, Y; Pan, L J; Hu, N B; Qu, S Q; Li, B; Xiao, Z J.

Affiliation

Xu ZF; Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China.

Zhonghua Xue Ye Xue Za Zhi ; 38(7): 572-577, 2017 Jul 14.

Article in Zh | MEDLINE | ID: mdl-28810323

Subject(s)

Decitabine/therapeutic use; Myelodysplastic Syndromes/drug therapy; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Retrospective Studies; Treatment Outcome

Key words

Antineoplastic combined chemotherapy protocols; Decitabine; Drug toxicity; Myelodysplastic syndromes; Treatment outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Decitabine Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: Zh Journal: Zhonghua Xue Ye Xue Za Zhi Year: 2017 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google